Omalizumab: A useful tool for inducing tolerance to bee venom immunotherapy

This publication has 14 references indexed in Scilit:

• Anaphylaxis to Insect Stings
  Immunology and Allergy Clinics of North America, 2015
• The Bee Sting That Was Not: An Unusual Case of Hymenoptera Anaphylaxis Averted in a Patient Treated with Omalizumab for Asthma
  Case Reports in Medicine, 2014
• Omalizumab mitigates anaphylaxis during ultrarush honey bee venom immunotherapy in monoclonal mast cell activation syndrome
  The Journal of Allergy and Clinical Immunology: In Practice, 2013
• Omalizumab and hypersensitivity reactions
  Current Opinion in Allergy and Clinical Immunology, 2013
• Venom immunotherapy for preventing allergic reactions to insect stings
  Cochrane Database of Systematic Reviews, 2012
• Omalizumab monotherapy for bee sting and unprovoked “anaphylaxis” in a patient with systemic mastocytosis and undetectable specific IgE
  Annals of Allergy, Asthma & Immunology, 2010
• Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma
  Journal of Allergy and Clinical Immunology, 2010
• Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co‐morbid seasonal allergic asthma
  Clinical & Experimental Allergy, 2009
• Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab.
  2009
• Side‐effects of insect venom immunotherapy:results from an EAACI multicenter study
  Allergy, 2000